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1School of Clinical Sciences, University of Bristol, Research Floor Level Seven, Bristol Royal Inﬁrmary, Upper Maudlin St., Bristol BS2 8HW, UKApproximately 50% of coronary artery bypass grafts using the
autologous saphenous vein fail within 10 years due to intimal
thickening. This study examined whether a gene therapy
approach that selectively kills Wnt/b-catenin/T cell factor
(TCF) activated vascular smooth muscle cells (VSMCs) using
dominant-negative N-cadherin (dn-N-cadherin) reduced
intimal thickening. Cultured human VSMCs infected with an
adenovirus (Ad) encoding dn-N-cadherin via the TCF pro-
moter (Ad-TOP-dn-N-cadherin) speciﬁcally expressed dn-N-
cadherin in response to activation of the Wnt/b-catenin/TCF
pathway. Infection with Ad-TOP-dn-N-cadherin signiﬁcantly
increased VSMC apoptosis (3 ± 0.2% versus 9 ± 0.7%;
p < 0.05, n = 6) and signiﬁcantly inhibited VSMC migration
by 83 ± 15% (p < 0.05, n = 6), but did not affect VSMC prolif-
eration (p > 0.05, n = 5). In an ex vivo human saphenous vein
organ culture model, luminal delivery of Ad-TOP-dn-N-
cadherin signiﬁcantly increased VSMC apoptosis after 7 days
of culture (4 ± 1.4% versus 9 ± 1.6%; p < 0.01, n = 6) and sup-
pressed intimal thickening by 75 ± 7% (p < 0.05, n = 5),
without a detrimental effect on endothelial cell coverage.
In vivo, Ad-TOP-dn-N-cadherin signiﬁcantly reduced intimal
thickening at day 21 (n = 10) in comparison to the Ad-b-galac-
tosidase (Ad-b-gal) control virus (n = 12, p < 0.05) in the
mouse carotid artery ligation model. In summary, we have
developed a novel approach to selectively reduce intimal thick-
ening, which may be beneﬁcial in reducing late vein graft
failure.Received 5 April 2017; accepted 27 April 2017;
http://dx.doi.org/10.1016/j.omtm.2017.04.009.
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Coronary artery bypass grafting (CABG) remains the mainstay treat-
ment for coronary artery disease to bypass diseased coronary arteries
and resume normal blood ﬂow to the heart. The saphenous vein is the
most widely used bypass conduit; however, late vein graft failure due
to intimal thickening and superimposed atherosclerosis remains a
signiﬁcant clinical problem and ﬁnancial burden for the healthcare
system.1,2 Intimal thickening reduces vein graft patency and is char-
acterized by the migration of vascular smooth muscle cells (VSMCs)
from themedia to the intima, where they proliferate and secrete extra-
cellular matrix. This ultimately leads to failure of the graft and recur-
rence of symptoms. Consequently, new therapies to reduce intimal
thickening are desirable.Molecular Therapy: Methods
This is an open access article under the CC BY-NC-N-cadherin is a member of the cadherin family of cell-surface recep-
tors that structurally link cells via physical interaction between their
extracellular domains. We previously reported that overexpression
of dominant-negative N-cadherin (dn-N-cadherin), which consists
of amino acids 6–27 (the cytoplasmic and transmembrane domains),
in isolated VSMCs promoted apoptosis and reduced intimal thick-
ening ex vivo.3 We have also identiﬁed Wnt/b-catenin/T cell factor
(TCF) signaling as a modulator of VSMC phenotype and contributor
to intimal thickening.3,4 In consideration of our previous ﬁndings, we
have developed an adenovirus (Ad)-based vector, in which the pro-
apoptotic dn-N-cadherin gene was driven by a Wnt/b-catenin/
TCF-responsive promoter linked to a minimal cytomegalovirus
(CMV) promoter. We hypothesized that introduction of Ad-TOP-
dn-N-cadherin (Ad-TOP-dn-N-cad) would reduce VSMC accumula-
tion and impair neointima formation in both our ex vivo human
saphenous vein (HSV) organ culture model and our in vivo mouse
carotid artery ligation model. This suicide gene approach, targeted
at speciﬁcally killing Wnt/b-catenin/TCF-activated VSMCs and pre-
serving non-activated VSMCs, is similar to that successfully em-
ployed by Williams et al.4 and Kwong et al.5 We report that Wnt/
b-catenin/TCF-driven expression of dn-N-cadherin promoted
apoptosis in b-catenin-activated VSMCs in vitro and effectively
retarded neointima formation in saphenous vein organ cultures and
ligated mouse carotid arteries. These data highlight the translational
potential of our strategy in preventing saphenous vein graft degener-
ation and secondary cardiac events.RESULTS
Characterization of Ad-TOP-dn-N-cadherin In Vitro
The dn-N-cadherin protein was detected by western blotting in
VSMCs infected with 1,000 pfu/cell of Ad-TOP-dn-N-cad and
stimulated with 10 mM lithium chloride (LiCl) (glycogen synthase
kinase 3 beta [GSK-3b] inhibitor; Figure 1A). No expression of
dn-N-cadherin was observed when VSMCs were infected with& Clinical Development Vol. 5 June 2017 ª 2017 The Author(s). 191
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. dn-N-cadherin Protein Expression Was Regulated by Activation and Inhibition of the Wnt/TCF Pathway in Isolated VSMCs
(A) Representative western blot for full-length N-cadherin, dn-N-cadherin, and b-actin (loading control) in VSMCs infected with Ad-TOP-dn-N-cadherin and stimulated with
10 mMLiCl to activateWnt signaling. * indicates a significant difference from control, paired Student’s t test, n = 3. (B and C) VSMCs infected with Ad-TOP-dn-N-cadherin and
Ad-dn-TCF-4 (B) or Ad-ICAT (C) to inhibit Wnt signaling in the presence of LiCl. Bar charts show densitometry. * indicates a significant difference fromAd-b-gal control, paired
Student’s t test, n = 3 (B) and n = 4 (C). Error bars represent SEM.
Molecular Therapy: Methods & Clinical DevelopmentAd-TOP-dn-N-cad without LiCl stimulation (Figure 1A: control) or
in VSMCs infected with Ad-b-galactosidase (Ad-b-gal) (Figure 1B:
control virus). Inhibition of Wnt signaling with Ad-dn-TCF-4 or
Ad-inhibitor of b-catenin and TCF-4 (Ad-ICAT) signiﬁcantly
reduced the level of expression of dn-N-cadherin (Figures 1B and
1C, respectively).
Ad-TOP-dn-N-cadherin Significantly Induced VSMC Apoptosis
Ad-TOP-dn-N-cadherin signiﬁcantly induced apoptosis in VSMCs.
In situ end labeling (ISEL) showed that apoptosis occurred in approx-
imately 9% of VSMCs infected with Ad-TOP-dn-N-cadherin in com-
parison to 3% with the Ad-b-gal control virus (Figure 2A). Similar
results were also detected by CC-3 immunocytochemistry, with
increased apoptosis in VSMCs infected with Ad-TOP-dn-N-cadherin
compared to VSMCs infected with the Ad-b-gal control virus (7.9 ± 1
versus 6.1 ± 1%, n = 3).192 Molecular Therapy: Methods & Clinical Development Vol. 5 June 20Ad-TOP-dn-N-cadherin Significantly Reduced VSMC Migration
but Had No Effect on VSMC Proliferation
We assessed the effect of Ad-TOP-dn-N-cadherin infection on
VSMC migration using the scratch-wound assay. Ad-TOP-dn-N-
cadherin signiﬁcantly reduced VSMC migration in comparison to
Ad-b-gal at 24 hr (Figure 2B). We next determined the effect of
Ad-TOP-dn-N-cadherin on VSMC proliferation. Bromodeoxyuri-
dine (BrdU) immunocytochemistry showed that there was no signif-
icant difference in proliferation between Ad-TOP-dn-N-cadherin
and Ad-b-gal (Figure 2C).
Ad-TOP-dn-N-cadherin Significantly Reduced Neointima
Formation in HSV Organ Cultures
Expression of b-galactosidase was detected at both 3 and 7 days
after infection in the majority of the cells on the surface of
the vein segments and was undetectable in the uninfected vein17
Figure 2. Regulated dn-N-cadherin Expression
Induced Apoptosis and Retarded VSMC Migration
but Did Not Affect Proliferation
(A) Representative images of in situ end labeling to detect
apoptotic cells after infection with Ad-b-Gal or Ad-TOP-
dn-N-cad. Arrows indicate apoptotic cells. Chart shows
percentage of apoptotic VSMCs. (B) Representative
images of scratch-would assay 24 hr after wounding
in VSMC infected with Ad-b-Gal or Ad-TOP-dn-N-
cad. Chart shows migration from the wound edge.
(C) Representative images of BrdU incorporation within
24 hr in VSMCs infected with Ad-b-Gal or Ad-TOP-dn-N-
cadherin. Arrows indicate some BrdU-positive cells.
Chart shows percentage of proliferation (BrdU positive).
* indicates a significant difference from Ad-b-Gal control.
n = 5 (A and C) and n = 6 (B), p < 0.05, paired Student’s
t test. Scale bars, 20 mm (A and C) and 50 mm (B). Error
bars represent SEM.
www.moleculartherapy.orgsegments (Figures S3A–S3D). ISEL of transverse tissue sections
demonstrated that infection of HSV segments with Ad-TOP-
dn-N-cadherin signiﬁcantly increased intimal cell apoptosis at
day 7 in comparison to the Ad-b-gal control virus (Figure 3A).
Moreover, infection with Ad-TOP-dn-N-cadherin signiﬁcantly
reduced intimal thickening by day 7, as visualized by elastic
van Gieson (EVG) staining (Figure 3B). QBend-10 immunohisto-
chemistry showed a signiﬁcant increase in endothelial cell (EC)
coverage after infection with Ad-TOP-dn-N-cadherin by day 7 in
comparison to Ad-b-gal control virus (Figure 3C). Ad-TOP-dn-
N-cadherin infection did not inﬂuence VSMC proliferation or
migration or medial apoptosis in the organ culture model (Table 1;
Figure S2).
Ad-TOP-dn-N-cadherin Promoted EC Migration
We assessed the effect of Ad-TOP-dn-N-cadherin infection on EC
migration using the scratch-wound assay. Ad-TOP-dn-N-cadherin
signiﬁcantly increased human umbilical vein endothelial cell
(HUVEC) migration in comparison to Ad-b-gal at 24 hr (Figure 4).
Importantly, this was suppressed by overexpression of the b-catenin
signaling inhibitor dn-TCF4 (Figure 4). Moreover, Ad-TOP-dn-N-Molecular Therapy: Methodscadherin did not signiﬁcantly affect apoptosis
rates compared to Ad-b-gal (6 ± 1% versus
7 ± 2%).
Ad-TOP-dn-N-cadherin Significantly
Reduced Neointima Formation after
Ligation of Mouse Carotid Arteries
Expression of b-galactosidase was detected at
3 days after infection in the majority of the cells
within the artery and was undetectable in the
uninfected artery (Figures S3E and S3F).
Ad-TOP-dn-N-cadherin transgene delivery to a
ligated mouse carotid artery resulted in signiﬁ-cantly increased numbers of apoptotic cells at 3 days after delivery
(Figures 5A and 5B) and a signiﬁcant reduction in intimal thickening
at day 21 post-surgery in comparison to mice infected with Ad-b-gal
(Figures 5C and 5D).
DISCUSSION
This study presents the development of an “activated” VSMC-tar-
geted suicide gene approach to inhibit intimal thickening within a
vein graft, similar to that described by Williams et al.4 In a previous
study, we identiﬁed a signiﬁcant increase inWnt/b-catenin/TCF-acti-
vated VSMCs in the media at 3 days and in the media and intima at
28 days after carotid artery ligation. We have previously shown that
Wnt/b-catenin/TCF-activated VSMCs display higher migratory and
proliferative rates and thereby contribute to intimal thickening.6,7
Williams et al.4 demonstrated that Ad-mediated delivery of the
thymidine kinase (TK) gene driven by aWnt/b-catenin/TCF-respon-
sive promoter suppressed neointima formation in ligated carotid
arteries of mice infused with ganciclovir. Selective death of Wnt/
b-catenin/TCF-activated VSMCs was achieved by TK-dependent
conversion of the prodrug ganciclovir into a toxic ganciclovir triphos-
phate. In this current study, we avoid the use of ganciclovir because it& Clinical Development Vol. 5 June 2017 193
Figure 3. Overexpression of Ad-TOP-dn-N-cadherin
in Human Saphenous Vein Organ Cultures
Significantly Induced VSMC Apoptosis,
Suppressed Intimal Thickening, and Enhanced
Endothelial Coverage
HSV was infected with Ad-b-gal or Ad-TOP-dn-N-cad
and cultured for 7 days. (A) Representative images show
apoptotic intimal cells detected by in situ end labeling
(brown, arrows indicate some positive cells). Chart shows
percentage of apoptotic cells. (B) Representative images
show EVG staining, white arrows indicate intima:medial
boundary, and black arrows indicate intimal surface.
Chart shows neointima thickness. (C) Representative
images of EC coverage detected by QBend-10 immu-
nohistochemistry (brown, arrows indicate some of the
endothelial cells). * indicates a significant difference from
Ad-b-gal control. n = 6 (A), n = 5 (B), and n = 7 (C),
p < 0.05, paired Student’s t test. Scale bar, 20 mm;
applies to all panels. Error bars represent SEM.
Molecular Therapy: Methods & Clinical Developmentis not suitable for long-term use in humans and it has potential off-
target effects. Instead, we employ dn-N-cadherin as a suicide gene
to improve the potential for translation to a clinical setting. dn-N-
cadherin was selected as the suicide gene because our previous works
have determined that its overexpression in isolated VSMCs induced
apoptotic cell death and thereby suppressed intimal thickening.3
We developed an Ad delivery of a dn-N-cadherin transgene under
the control of a Wnt/b-catenin/TCF-speciﬁc promoter. This
approach also conﬁrms in both ex vivo and in vivo models that
Wnt/b-catenin/TCF signaling is important for intimal thickening
and apoptosis ofWnt/b-catenin/TCF-activated VSMCs effectively re-
duces intimal thickening.4
Mechanistically, we show in isolated VSMCs that overexpression of
dn-N-cadherin, under the control of a Wnt/b-catenin/TCF-respon-
sive promoter, increased apoptosis and reduced migration, but had
no effect on proliferation. Expression of dn-N-cadherin in Ad-
TOP-dn-N-cadherin-infected VSMCs was induced with LiCl, which
inhibits the GSK-3b inhibitor and activates b-catenin; conversely,
transactivation of Ad-TOP-dn-N-cadherin was abrogated with co-194 Molecular Therapy: Methods & Clinical Development Vol. 5 June 2017infection of Ad-dn-TCF-4 and Ad-ICAT, which
both disrupt Wnt/b-catenin/TCF signaling.
Thus, we demonstrated that expression of
the pro-apoptotic dn-N-cadherin transgene
required enhanced b-catenin signaling and so
allowed selective killing of Wnt/b-catenin/
TCF-activated VSMCs.
We examined the effects of the Ad-TOP-dn-N-
cadherin on intimal thickening using a well-
established HSV organ culture model.8,9 After
7 days of culture, Ad-TOP-dn-N-cadherin
signiﬁcantly suppressed neointima formation
and induced apoptotic cell death, but no effecton VSMC migration and proliferation was noted in organ cultures.
We propose that dn-N-cadherin retarded neointima formation by
inducing apoptosis in VSMCs that exhibit b-catenin/TCF-signaling
activity. By inducing apoptosis of medial VSMCs, there are fewer
VSMCs to migrate to the intima, where they proliferate and deposit
matrix and cause neointimal thickening. This conﬁrms our previously
proposed pro-apoptotic approach for suppression of neointimal for-
mation using TIMP-3 overexpression and dn-N-cadherin.3,10 It
further highlights that selection of activated VSMCs with b-cate-
nin/TCF signaling retains the effectiveness of dn-N-cadherin to
reduce neointima formation.
Damaged endothelium is detrimental in both early and late vein graft
failure because it contributes to thrombosis formation in early vein
graft failure, neointimal formation, and super-imposed atheroscle-
rosis, which is the cause of late graft failure.11 Consequently, preser-
vation of endothelial coverage of the vein graft is of great importance.
Interestingly, we observed a signiﬁcant increase in EC coverage in the
Ad-TOP-dn-N-cadherin-infected vein, so performed in vitro studies
to determine changes in EC behavior. This is in contrast to our
Table 1. Effect of Ad-TOP-dn-N-cad on HSV Organ Cultures
Ad-b-gal Ad-TOP-dn-N-cad
Total number of intimal cells/mm 10.0 ± 1.5 3.9 ± 1.0a
Intimal proliferation (%) 18.7 ± 6.8 19.7 ± 3.7
Medial proliferation (%) 7.3 ± 2.1 7.9 ± 2.6
Migration (% BrdU ve/mm) 0.042 ± 0.09 0.040 ± 0.005
Medial apoptosis 12.3 ± 5.4 13.3 ± 4.6
Segments of human saphenous vein were infected with Ad-TOP-dn-N-cad or Ad-b-gal
and cultured for 7 days prior to analysis, n = 6.
aIndicates signiﬁcant difference (paired Student’s t test, p < 0.05).
www.moleculartherapy.orgprevious observations with Ad-TIMP-3, in which EC coverage was
unaffected by overexpression of this transgene.10 Despite a compara-
ble reduction in the neointima area with Ad-TIMP-310 and Ad-TOP-
dn-N-cadherin, we consider that the use of TOP-dn-N-cadherin is
more advantageous because only Ad-TOP-dn-N-cadherin caused
increased endothelial cell coverage, which may contribute to reduced
thrombus formation and neointima development.
In cultured HUVECs, overexpression of dn-N-cadherin had no ef-
fect on apoptosis but signiﬁcantly enhanced migration; this induc-
tion was lost with co-infection with Ad-dn-TCF4, a b-catenin/
TCF signaling inhibitor. Interestingly, these observations in EC con-
trasted with the inhibitory effect on VSMC migration. We have pre-
viously demonstrated that dn-N-cadherin signiﬁcantly retarded
VSMC migration via induction of VSMC apoptosis3 because there
are fewer VSMCs to migrate. Although ECs express N-cadherin
on the basolateral surface, with which they interact with VSMCs,
they predominantly express VE-cadherin to form homophilic con-
tacts. We therefore propose the differing effects of dn-N-cadherin
on these two cell types are due to the difference in cadherin
expression.
In order to evaluate the translational potential of our gene therapy
in terms of reducing intimal thickening, we tested Ad-TOP-dn-N-
cadherin in an in vivo mouse model. Due to the lack of a suitable
mouse model of vein grafting that adequately represents the human
remodeling process and neointima formation, we consider that the
carotid artery ligation model is the most appropriate for testing the
efﬁcacy of TOP-dn-N-cadherin. Unfortunately, the mouse vein
graft model12 is not suited for this study because the majority
of the medial VSMCs in the graft die within the ﬁrst few days
after graft implantation, and intimal thickening in this model is
the result of repopulation of the graft material. This is in contrast
to the remodeling of human vein grafts, in which complete loss
of medial VSMCs does not occur. Consequently, our approach
to induce death of graft medial cells would not work in this
model and therefore we selected to utilize the carotid artery
ligation model, which is well established for investigating VSMC
migration and proliferation and vascular remodeling at the
molecular level.13 Blood ﬂow in the left common carotid artery is
disrupted by ligating the vessel near the distal bifurcation. ThisMolecucauses vascular remodeling, promoting VSMC migration and
proliferation and the development of an intimal lesion (intimal
thickening). Compared to Ad-b-gal, Ad-TOP-dn-N-cadherin
signiﬁcantly reduced intimal thickening. The media of ligated
vessels appeared structurally normal. Interestingly, neointimal
area was more effectively attenuated by Ad-TOP-dn-N-cadherin
(70%) than by Ad-TK (40%).4
In summary, we have demonstrated that Ad delivery of a dn-N-cad-
herin transgene, under the control of a Wnt/b-catenin/TCF-speciﬁc
promoter (Ad-TOP-dn-N-cadherin), increased VSMC apoptosis
and reduced intimal thickening both ex vivo and in vivo. Intra-
operative gene transfer of dn-N-cadherin for selective death of
Wnt/b-catenin/TCF-activated VSMCs may hold promise for
reducing incidences of restenosis after CABG. This procedure is
particularly amenable to gene therapy because the vein can be in-
fected ex vivo prior to implantation, which avoids in situ or systemic
delivery and restricts exposure to the Ad.MATERIALS AND METHODS
Generation of Wnt/b-catenin/TCF-Responsive dn-N-cadherin
Construct Ad-TOP-dn-N-cadherin
The original Xenopus dn-N-cadherin cDNA was obtained from a
cvpSP72DNcadC construct, a kind gift from Dr. L. Weitzmann,
Washington University. The dn phenotype was generated by deletion
of the extracellular domain, retaining the transmembrane and cyto-
solic domains.14 The dn-N-cadherin cDNA was removed from the
cvpSP272 vector by XhoI and EcoRV digestion, yielding a 1,201-nt
fragment. In order to clone dn-N-cadherin into the pDC512 destina-
tion vector (Microbix), dn-N-cadherin was sub-cloned into a pGEMT
Easy Vector (Promega) by TA cloning. The dn-N-cadherin fragment
was removed by EcoRI digestion and ligated into pDC512 (also EcoRI
digested and de-phosphatased by calf intestinal phosphatase [CIP]
[NEB]). The 250-nt minimal cytomegalovirus (minCMV) promoter
was generated from murine CMV (MCMV) cDNA of the pDC516
vector (Microbix) and ampliﬁed by PCR (incorporating HindIII
and NheI restriction sites) using KOD (high ﬁdelity) polymerase
and the following primers:
(forward) 50-AAGCTTTAGGGCCAGTACATAAGGTCAAT
AG-30 and
(reverse) 50-GCTAGCCTGACTGCATTAGTTTCAATAGC-30.
Amplicons were cloned into the pGEMT Easy Vector by TA
cloning and ligated using the Roche Ligation Kit (Roche Life
Science). The minCMV/pGEMT construct was digested with
HindIII, blunted with mung bean nuclease, and digested with
NheI (high ﬁdelity) to remove the minCMV and produce com-
patible ends for ligation. The DNcadCpDC512 was digested with
BglII, blunted with mung bean nuclease, and digested with NheI
before treatment with CIP and ligation with the minCMV. The
M50 Super 8x TOPFlash promoter (Addgene plasmid 12456) con-
taining seven TCF/lymphoid enhancing factor-1 (LEF-1)-bindinglar Therapy: Methods & Clinical Development Vol. 5 June 2017 195
Figure 4. Regulated dn-N-cadherin Expression
Promoted EC Migration
(A) Representative images of the wounding assay performed
in HUVECs infected with Ad-b-gal or Ad-TOP-dn-N-cad,
with or without Ad-b-gal or Ad-dn-TCF4. Scale bar, 100 mm;
applies to all panels. (B) The distance from the wound edge
after 24 hr was measured. * indicates a significant difference
from Ad-b-Gal control; $ indicates a significant difference
from Ad-TOP-dn-N-cad+Ad-b-Gal, n = 4, p < 0.05, ANOVA
and Student Newman Keuls post hoc test. Error bars
represent SEM.
Molecular Therapy: Methods & Clinical Developmentsites was ampliﬁed by PCR to generate a 147-nt amplicon using the
following primers:
(forward) 50-GCGTCTAGAGGTACCGAGCTCTTACGCG-30 and
(reverse) 50-GCGGTCGACCCCTCTAGAGTCTAGATCTCG-30.
Amplicons were digested with SalI. The dn-N-cadherinpDC512-
minCMV was digested with SalI and de-phosphatased with CIP.
The TOPFlash and dn-N-cadherinpDC512minCMV fragments
were ligated to generate a TOPminCMVdn-N-cadherin construct.
All recombinants were conﬁrmed by direct sequencing. The plasmid
map is shown in Figure S1.
Ad Vectors
Replication-defective Ads based on the Ad-5 vector were used for this
study: Ad-TOP-dn-N-cadherin, control Ad-b-gal, Ad-ICAT, and
Ad-dn-TCF4. Ad-TOP-dn-N-cadherin consists of a Wnt/b-catenin/
TCF-responsive promoter (TOP) controlling the dn (truncated)
N-cadherin. Ad-b-gal encodes the bacterial lacZ gene under the con-
trol of the CMV immediate early promoter and was used as a control
adenovirus. Ad-ICAT and Ad-dn-TCF4 encode ICAT and dnTCF-4,
respectively, and are described previously.15 Plaque-pure viruses were
propagated on HEK293 cells, puriﬁed by caesium chloride density
gradient centrifugation, and titered using the end-point dilution196 Molecular Therapy: Methods & Clinical Development Vol. 5 June 2017assay. Recombinant Ads were tested for replica-
tion deﬁciency by titration on non-permissive
HeLa cells. In addition, all preparations of Ads
were tested for functional transgene production
and lack of toxicity in isolated VSMCs in vitro.
Stocks were stored at 70C in aliquots and
thawed immediately before use.
Cell Culture
Saphenous vein segments surplus to surgical re-
quirements were obtained from patients undergo-
ing coronary artery bypass surgery (REC number
12/SW/0306). HSV VSMCs were grown as
described previously.16 VSMCs were maintained
in growth media (DMEM supplemented with
100 mg/mL of penicillin, 100 IU/mL streptomycin,
2 mM L-glutamine, and 10% [v/v] fetal calf serum[FCS]). When required, (canonical) Wnt signaling was induced with
10 mM LiCl. Four batches of pooled populations of HUVECs were
purchased from Promocell and cultured as recommended by the
supplier.
Total Protein Extraction
VSMC proteins were extracted from cells with 1% (w/v) SDS lysis
buffer. Each well was scraped with a pipette tip and lysates were ho-
mogenized by a syringe needle and centrifuged at 13,000 g for 5min
to remove cell debris. The protein concentration of the supernatant
was determined using the bicinchoninic acid (BCA) protein assay
kit (Thermo Scientiﬁc). Equal protein concentrations were then sub-
jected to western blotting.
Infection with Ads
Cells were seeded in 12-well tissue culture plates at a density of 8 104
cells/well. For overexpression of Ad-dn-N-cadherin, cells were in-
fected with 100, 300, and 1,000 plaque-forming units (pfu) per cell
(0.1  108, 0.33  108, and 1  108 per mL) of Ad-TOP-dn-N-cad-
herin or Ad-b-gal (control virus) in growthmedia. For nuclear inhibi-
tion of Wnt/b-catenin/TCF signaling, cells were also infected with
300 pfu/cell of Ad-ICAT or Ad-dn-TCF-4. After 18 hr, fresh growth
media was added to induceWnt/b-catenin/TCF signaling for a further
24 hr before cell lysis for western blot analysis.
Figure 5. Ad-TOP-dn-N-cadherin Transgene
Delivery in a Mouse Carotid Artery Ligation Model
Significantly Increased Apoptosis and Reduced
Neointimal Thickening
Adenoviral delivery of Ad-b-Gal transgene in Pluronic
F-127 gel to a ligated carotid artery and adenoviral de-
livery of Ad-TOP-dn-N-cad transgene. (A) Representative
cleaved caspase-3 immunohistochemistry at 3 days.
Arrows indicate positive cells (green); nuclei are stained
blue with DAPI. Scale bar, 25 mm; applies to both panels.
Dotted line indicates the lumenal surface. (B) Quantifica-
tion of cleaved caspase-3 positive cells. * indicates a
significant difference from Ad-b-Gal control, p < 0.05,
Student’s t test, n = 4 per group. (C) Representative im-
ages show neointimal thickening in Miller’s EVG-stained
sections at 21 days. Dotted line indicates the intimal:
medial boundary. Scale bar, 200 mm; applies to both
panels. (D) Quantification of neointimal area at 21 days.
* indicates a significant difference from Ad-b-Gal control,
p < 0.05, n = 12 (Ad-b-Gal) and n = 10 (Ad-TOP-dn-N-
cad), Student’s t test. Error bars represent SEM.
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Cell lysates were loaded on 3%–8% polyacrylamide Mini-PROTEAN
Precast Gels (BIO-RAD) and transferred using the Trans-Blot Turbo
System. Nitrocellulose membranes were blocked in 2% (w/v) BSA in
Tris-buffered saline, 0.1% Tween 20 (TBS-T). Blots were incubated
overnight at 4C with 0.1 mg/mL of mouse anti-N-cadherin antibody
(BD Transduction Laboratories, 610921), which recognizes the C-ter-
minal (intracellular) domain. Bound antibodies were detected using
goat anti-mouse horseradish peroxidase (HRP) conjugated antibody
(DAKO) diluted 1:2,000 in 2% BSA in TBS-T and enhanced chemilu-
minescence (Luminata Forte Western HRP Substrate, Merck Milli-
pore). To assess equal protein loading, blots were subsequently
incubated with 0.11 mg/mL of mouse anti-b-actin antibody (Sigma,
A5316). Bound antibodies were detected with rabbit anti-mouse
HRP (DAKO) and enhanced chemiluminescence as described above.
Densitometry using a GS-690 densitometer (BIO-RAD) was used to
quantify detected bands (optical density [OD]  mm2).Molecular Therapy: MethodsApoptosis
VSMCs were ﬁxed as previously described
above. Apoptotic VSMCs were identiﬁed by
ISEL and cleaved caspase-3 immunocytochem-
istry as previously described.17 The number of
positive (apoptotic) cells was expressed as a
percentage of the total number of cells in 15
0.25 mm2 ﬁelds using the Media Cybernetics
Image Pro Plus version 3 image analysis system
(Data Cell).
Cell Proliferation
Cells were seeded onto coverslips in 24-well tis-
sue culture plates at a density of 4  104 cells/
well and cultured in growth media for 30 hr.
VSMCs were then infected with 1,000 pfu/cellof Ad-TOP-dn-N-cadherin or Ad-b-gal control virus in growth
media. After 18 hr, the media was replaced with fresh growth media
supplemented with 10 mMBrdU. The cells were ﬁxed after 24 hr with
ice-coldmethanol for 5min. Hydrochloric (HCl) acid (4N) was added
to each well and incubated for 30 min at 37C. VSMCs were then
incubated with 1 mM mouse anti-BrdU, (Sigma, B2531) in 1% (v/v)
goat serum and 1% (w/v) BSA/PBS at 4C overnight. Cells were
then incubated with biotinylated goat anti-mouse antibody diluted
1:200 in 1% BSA/PBS for 30 min at room temperature and then
Extravidin-HRP diluted 1:200 in 1% BSA/PBS for 30 min at room
temperature. The color was developed with 3,30-diaminobenzidine
(DAB) solution as described above by incubating for 10 min. VSMCs
were counterstained with hematoxylin and washed well with tap
water. Coverslips were mounted onto glass slides with polyvinylpyr-
rolidone (PVP). Proliferation was measured by counting the number
of BrdU-positive (brown) cells and dividing by the total number of
cells in 20 0.25 mm2 ﬁelds using image analysis.& Clinical Development Vol. 5 June 2017 197
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VSMCs and HUVECs were seeded onto coverslips in 24-well tissue
culture plates at a density of 4 104 cells/well and cultured in growth
media for 30 hr. Cells were then infected with 1,000 pfu/cell of Ad-
TOP-dn-N-cadherin or Ad-b-gal control virus in growth media.
After 18 hr, cells were subjected to wounding by rubbing a 1 mL
pipette tip across the layer twice. The media was replaced with fresh
growth media supplemented with 2 mM hydroxyurea to suppress
proliferation, as previously described.3 A total of six images of
wounded and non-wounded areas were captured at 0 hr and 24 hr
using Image Pro Plus version 3. The distance migrated was measured
at 20 points along the wound edge using image analysis.
Organ Culture
HSV surplus segments were collected as detailed previously.8 The
vein was placed in wash medium (20 mM HEPES-buffered RPMI
1640 supplemented with 2 mM L-glutamine, 100 IU/mL penicillin,
and 100 mg/mL of streptomycin). The adventitial layer was removed,
and the vein was cut into three equal segments. One segment was in-
fected with Ad-TOP-dn-N-cadherin, and another segment was in-
fected with Ad-b-gal control virus. The vein was infused with
100 mL of 1.2  1010 pfu/mL of Ad-dn-N-cadherin or Ad-b-gal for
a period of 1 hr, as described previously.10,18,19 All three segments
were then opened longitudinally and cut transversely into three 5-
to 10 mm segments. Vein segments were cultured separately, with
the luminal surface facing upward for up to 14 days in organ culture
growth media (RPMI 1640 supplemented with 30% [v/v] FCS, 2 mM
L-glutamine, 100 IU/mL penicillin, 100 mg/mL streptomycin, and
10 mM BrdU). The tissue culture growth media was changed every
2 days. After 4, 7, or 14 days of culture, the vein segments were washed
in PBS and then ﬁxed in 10% (v/v) formalin in PBS prior to embed-
ding in parafﬁn wax, and the analysis was performed on at least three
different sections. Infection efﬁciency was monitored by X-gal stain-
ing for the b-galactosidase transgene, as described previously.18
Apoptosis: ISEL in Saphenous Vein Organ Cultures
Brieﬂy, 3-mmdeparafﬁnized, rehydrated sections were incubated with
5 mg/mL of proteinase K for 15 min at room temperature. Sections
were then incubated in reaction buffer containing 0.01 mM dATP,
dCTP, dGTP, and biotin-16-dUTP, 8 U/mL DNA polymerase I
(Klenow) large fragment, 50 mM Tris Cl pH 7.2, 10 mM MgSO4,
and 0.1mMDTT for 15min at 37C. After treating with 3% hydrogen
peroxide for 5 min, slides were incubated in extravidin HRP diluted
1:200 in 10% FCS in PBS for 30 min at room temperature and then
color developed with DAB solution for 10 min prior to counterstain-
ingwith hematoxylin for 2min. Slides werewashedwell with tapwater
and then dehydrated and cleared prior to mounting in DPX. The
number of positive (brown nuclei) cells (on the intimal surface and
in themedia) was expressed as a percentage of the total number of cells
across the entire length of the vein segment using image analysis.
Intimal Thickening
3-mm transverse sections were stained with Miller’s EVG. The intimal
area and length of each vein segment was measured by image analysis.198 Molecular Therapy: Methods & Clinical Development Vol. 5 June 20The average intimal thickness was determined by dividing the intimal
area by the length of each vein segment.
Cell Proliferation and Migration in Saphenous Vein Organ
Cultures
Proliferation was assessed in parafﬁn wax-embedded sections by
immunohistochemistry for incorporated BrdU. Sections (3 mm)
were incubated with 1% (v/v) goat serum and mouse 8.6 mg/mL of
anti-BrdU antibody (Sigma, B2531) in 1% BSA/PBS at 4C overnight.
Slides were incubated with biotinylated goat anti-mouse secondary
antibody, diluted 1:200 in 1% BSA/PBS for 30 min at room tempera-
ture and then extravidin-HRP diluted 1:200 in 1% BSA/PBS for
30 min at room temperature. Color was developed by incubation
with DAB for 10 min. VSMCs were counterstained with hematoxylin
and washed with tap water. Coverslips were mounted with PVP.
Quantiﬁcation of the BrdU incorporation was achieved by calculating
the percentage of BrdU-positive VSMCs in the media and intima.
Migration was estimated by counting the number of BrdU-negative
cells in the intima and dividing by the length of the vein segment
using image analysis, as in our previous studies.3,10,18–22 A represen-
tative image is shown in Figure S2.
EC Coverage
EC coverage was assessed by QBend-10 immunocytochemistry.
Deparafﬁnized, rehydrated sections (3 mm) were incubated with
3% (v/v) hydrogen peroxide for 5 min at 4C before blocking in
20% (v/v) goat serum in PBS for 30 min at room temperature.
Sections were incubated with 0.1 mg/mL anti-QBend-10 antibody
(Abcam, ab8536) in 1% (w/v) BSA in PBS overnight at 4C. Slides
were then incubated with biotinylated goat anti-mouse diluted
1:200 in 1% (w/v) BSA/PBS for 30 min at room temperature and
then extravidin-HRP diluted 1:200 in 1% (w/v) BSA/PBS for
30 min at room temperature. Slides were incubated with DAB for
10 min as above. VSMCs were counterstained with hematoxylin
and washed with tap water. Coverslips were mounted with PVP.
EC coverage was quantiﬁed by counting positive cells along the
luminal surface and dividing by the length of the segment.
In Vivo Analysis of Ad-dn-N-cadherin Transgene Delivery and
Effects on Intimal Thickening
The housing and care of all the animals and the procedures used in
these studies were performed in accordance with the guidelines and
regulations of the University of Bristol and the United Kingdom
Home Ofﬁce. The investigation conforms to the Guide for the Care
and Use of Laboratory Animals published by the US NIH (Publication
No. 85-23, revised 1996). Male, 8-week-old C57BL/6 mice (n = 30)
were subjected to a left common carotid artery ligation surgical pro-
cedure involving dissection and ligation near the carotid bifurcation
to induce intimal thickening, as described previously.6 To assess the
effects of Ad-TOP-dn-N-cadherin transgene delivery and intimal
thickening in vivo, mice were randomly divided into two groups
(n = 15 per group). One group received 2.2  1012 pfu/mouse of
Ad-TOP-dn-N-cadherin in 30% (v/v) Pluronic F-127 gel (Sigma Al-
drich). The other group received the same concentration of Ad-b-gal17
www.moleculartherapy.orgcontrol virus. The Ads were pipetted onto the ligated artery immedi-
ately after carotid artery ligation using an ice-cold pipette tip. After
surgery, the mice were housed within their experimental group as
trios for 21 days and fed a normal chow diet. At day 3 and 21, mice
were euthanized and left and right (non-ligated) carotid arteries
were harvested, ﬁxed in 10% formalin for 24 hr, and embedded in
parafﬁn wax in a longitudinal orientation for 21-day samples and
transversely for 3-day samples, as previously described.6 3-mm longi-
tudinal sections were stained with EVG. Intimal thickening was quan-
tiﬁed in the 21-day samples using image analysis, and the lumen area
was expressed as a percentage of the area within the internal elastic
lamina. Apoptotic cells and b-galactosidase protein were identiﬁed
in 3 mm transverse sections at 3 days using immunohistochemistry
for cleaved caspase-3 and b-galactosidase, as previously described.6,23
Statistical Analysis
Data are presented as n = independent experiments, as noted in the
ﬁgure legends. For analysis of two groups, paired or unpaired Stu-
dent’s t tests were employed. ANOVA and the Student Newman
Keuls post hoc test were performed when three or more groups of
data were analyzed. Data were considered statistically signiﬁcant
when p < 0.05.
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Supplementary Figure 1. Plasmid map of Ad-TOP-dn-N-cadherin.
The M50 Super 8x TOPFlash promoter (Addgene plasmid 12456) containing 7 TCF/LEF-1 binding sites was 
amplified by PCR to generate a 147 nt amplicon. The 250 nt minimal cytomegalovirus (minCMV) promoter 
generated from murine CMV (MCMV) cDNA of the pDC516 vector (Microbix) and cloned upstream of the 
dn-N-cadherin cDNA. The TOPFlash and dn-N-cadherinpDC512minCMV fragments were ligated to generate 
a TOPminCMVdn-N-cadherin construct that was cloned into the pDC512 destination vector (Microbix) for 
generation of Ad-TOP-dn-N-cadherin.
Ad-TOP-dn-N-cadAd-β-Gal
Supplementary Figure 2. Over-expression of Ad-TOP-dn-N-cadherin in human saphenous vein (HSV) 
organ cultures did not affect VSMC proliferation or migration. 
HSV was infected with Ad-b-galactosidase (A: Ad-b-gal) or Ad-TOP-dn-N-cadherin (B: Ad-TOP-dn-N-cad) 
and cultured for 7 days. Representative images show immunohistochemistry for BrdU incorporation 
(brown nuclei, black arrows indicate some positive cells). Migration was estimated by counting the number 
of BrdU negative intimal cells (blue nuclei, red arrows indicate some migrated cells). 
Scale bar represents 50 mm and applies to both panels.
A B
Supplementary Figure 3. Over-expression of Ad-b-Galactosidase in human saphenous vein (HSV) organ 
cultures and mouse ligated carotid artery (LCA) model. 
HSVs were infected with Ad-b-gal and cultured for 3 days (A) and 7 days (B) or uninfected and cultured for 
3 days (C) and 7 days (D). Representative images show X-gal staining (blue). Scale bar in panel A represents 
50 mm and applies to panels A-D. LCAs were infected with Ad-b-gal (E) or uninfected (F), and retrieved 
after 3 days.  Expression of transgene was detected with immunohistochemistry for b-galactosidase 
(green) and nuclei are stained blue with DAPI. Scale bar in panel E represents 20 mm and applies to panels 
E and F.
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Supplementary Figure 4. a-smooth muscle actin in ligated mouse carotid arteries.
Adenoviral delivery of Ad-β-Galactosidase (Ad-β-Gal) transgene in Pluronic F-127 gel to a ligated 
carotid artery and adenoviral delivery of Ad-TOP-dn-N-cadherin (Ad-TOP-dn-N-cad) transgene.
Representative a-smooth muscle actin immunohistochemistry at 21 days. Positive cells (green), 
nuclei are stained blue with DAPI. Dotted line indicates the intima:media boundary. Scale bar 
represents 25 mm and applies to both panels.
